A number of studies suggest that a cellular immunotherapy is already an established and curative therapy for acute myelogenous leukemia (AML). Recent data from nonablative allogeneic stem cell transplants for AML at MD Anderson demonstrate that there is a graft-versus-leukemia affect associated with graft-versus-host disease in patients who have allografts for this disease. However, graft-versus-host disease is associated with substantial toxicity. Attempts have therefore been made to improve immunotherapeutic approaches. One approach has been to take myeloid leukemia cells and culture them in the presence of cytokines to generate dendritic cells. These dendritic cells are then able to stimulate autologous and allogeneic cytotoxic T cells.
Dendritic cells exist in all tissues. They take up antigen, migrate to regional lymph nodes, and initiate primary T cellmediated immunity. They have abundant expression of core stimulatory molecules, CD80 and CD86, other adhesion molecules, and abundant surface class 1 and 2 major histocompatibility complex (MHC) protein. A number of studies are ongoing to utilize dendritic cells to present peptide antigens.
Leukemic dendritic cells have been cultured from crude mononuclear cell preparations from bone marrow or peripheral blood of 30 patients with chronic myelogenous leukemia (CML) and AML of all FAB subtypes, in the presence of GM-CSF, interleukin (IL)-4, and tumor necrosis factor (TNF)-␣. 1 More recently, CD40 ligand has been substituted for TNF-␣. After coculture with autologous T cells and expansion with IL-2, these cells were tested as effectors in cytolytic and other assays. After culture, the cells resemble dendritic cells and express CD80 and CD86, along with the other dendritic cellassociated markers, CD1A and CD83. Similar results were obtained with the TNF-containing combination, the cytokine combination, and the CD40 ligand-containing combination. Karyotypic analysis demonstrated that the dendritic cells were derived from the original leukemia cells. When they are used to stimulate autologous T cells in culture, the T cells are cytolytic for the original leukemia. 1 Recently, we have also been studying myelodysplastic syndromes and the ability of interferon-␣ to increase the terminal maturation of dendritic cells. We have demonstrated enhanced costimulatory molecule expression after interferon-␣ was added to the cultures.
Tumor cells from AML and many myelodysplastic syndromes, as well as the majority of CML cases, will show differentiation toward dendritic cells, which may stimulate autologous antileukemic cytotoxicity. This cytotoxicity is leukemiaspecific and, in CML, HLA-restricted as demonstrated by anti- The paradigm with this approach is that the leukemic dendritic cells are in fact presenting leukemia-associated antigens without the addition of exogenous peptides. We have initiated a clinical trial in which leukemic cells from patients with relapsed AML will be separated from T cells and then reinfused after a reinduction therapy. The patients will receive low-dose IL-2 and may potentially get subsequent cycles of therapy. The objective here is to determine a maximum tolerated dose and the feasibility of producing these cells on a clinical scale.
This therapy may also potentially be implemented in allogeneic transplantation. Data from the North American Donor Lymphocyte Registry of treatment of relapsed AML after allograft with donor lymphocyte infusion demonstrate only rare remissions, and most of those are not durable. When donor lymphocyte infusion is combined with chemotherapy, there are more complete remissions, but again, most are not durable. We are initiating a clinical trial in patients relapsing after allografts. Dendritic cells will be generated from the leukemic cells and then they will be used to activate donor lymphocytes. The expectation is that this will lead to an enhanced graft-versus-leukemia effect, but also increased graft-versushost disease. In preliminary experiments, we have addressed this issue by testing allogeneic donor lymphocytes grown up as a polyclonal line on patient dendritic cells in a proliferative assay against the original leukemia or nonmalignant and nonhematopoietic bone marrow stromal cells. There was substantially better proliferation in response to the leukemia than the stromal cells.
We have attempted to identify the target antigens for the autologous cytolytic cells in CML by looking at 24 different V-beta families by PCR. In the lymphocytes exposed to dendritic cells and IL-2, two peaks shared between two patients are of similar size; after reamplification with J-beta-specific internal primers, we see a single peak, which is the shared size and which in fact predicts for identical amino acid sequence. 2 These data suggest that the dendritic cells are stimulating a response directed against a relatively limited subset of antigens that appear to be shared between patients.
In conclusion, cellular immunotherapy is already an established and curative therapy for AML. There are now data suggesting possible ways to improve on the therapeutic index of cellular immunotherapy. Myeloid leukemia cells and myelodysplastic syndrome cells will in most cases differentiate toward dendritic cells, which will induce an autologous cytotoxicity that is leukemia-specific and HLA-restricted. These findings have now been confirmed by other groups. 3, 4 Thus, clinical trials are urgently needed to examine the therapeutic activity of these cells. We may expect therapeutic activity to be most active in situations of disease remission. Residual, clonogenic leukemia is much more likely to respond than disease in frank relapse. Vaccination strategies administering leukemia-derived dendritic cells after remission induction may well much reduce the incidence of relapse of patients with poor prognosis forms of AML or MDS. We are ourselves pursuing the administration of dendritic cell-activated autologous lymphocytes for the treatment of these patients. The target antigens presented by dendritic cells appear to be limited in number and shared between patients. Potentially, we will be able to identify these target antigens and exploit them in a therapeutic strategy. This may ultimately allow the identification of a series of leukemia-related antigens that might prove active as a cell-free vaccine.
